Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
featured
  • 220 views
  • 25 Mar, 2021
  • 1 location
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in

  • 0 views
  • 26 Jan, 2021
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

  • 1 views
  • 29 Jan, 2021
  • 1 location
  • 82 views
  • 25 Apr, 2021
  • 12 locations
Salvage Therapy With Sunitinib Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

sutent was approved to effective by two phase II trials in advanced renal cell carcinoma patients after failure of immunotherapies, and one phase III trial in treatment-naive advanced renal

docetaxel
serum bilirubin level
ct scan
neutrophil count
lung carcinoma
  • 2 views
  • 08 Nov, 2020
  • 1 location
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1

  • 0 views
  • 13 Jun, 2021
  • 5 locations
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

activity for cabozantinib in patients with advanced renal cell carcinoma and metastatic castration-resistant prostate cancer (mCRPC). Furthermore, in preclinical models of urothelial carcinoma (UC) of the

bladder cancer
RET
KIT
neutrophil count
advanced urothelial carcinoma
  • 46 views
  • 26 Jan, 2021
  • 12 locations
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma.

  • 70 views
  • 08 May, 2021
  • 16 locations
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The

programmed cell death 1 ligand 1
advanced renal cell carcinoma
growth factor
kinase inhibitor
measurable disease
  • 0 views
  • 20 May, 2021
  • 38 locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

everolimus
programmed cell death 1 ligand 1
advanced renal cell carcinoma
growth factor
clear cell renal cell carcinoma
  • 168 views
  • 13 Jun, 2021
  • 178 locations